Themis Medicare

THEMISMED · NSE

— · —

₹119.95

Closing price — 29 Sept 2026

Market cap ₹1,113 Cr · EPS ₹3.22

Valuation

Blended fair value using DCF and peer comparison methods.

See if Themis Medicare is undervalued

Unlock intrinsic value for 4,800+ Indian stocks — free.

The intrinsic value shown is an algorithmic estimate based on publicly available financial data — including DCF analysis, peer comparison, and historical financials. It is not a research report, investment advice, or a recommendation to buy, sell, or hold any security. Stock valuations involve uncertainty and may differ significantly from market prices. Please consult a SEBI-registered investment adviser before making any investment decision.

Peer comparison

How this company stacks up against sector peers on valuation and quality metrics.

Branded generics & specialty pharma · 8 peers · sector medians shown

Better than medianWorse than median

Company	Mkt Cap	P/E	P/B	EV/EBITDA	ROE	Net Margin	Rev CAGR 3y
Themis Medicare THEMISMED · you	₹1,112 Cr	37.1×	3.4×	—	9.2%	0.3%	—
Sector median	—	38.4×	4.5×	19.3×	10.1%	11.8%	13.6%
Aarti Pharmalabs Limited AARTIPHARM	₹7,617 Cr	35.9×	3.0×	20.4×	8.2%	9.6%	-2.2%
Shilpa Medicare Limited SHILPAMED	₹7,366 Cr	47.5×	4.5×	18.2×	9.4%	15.8%	13.6%
Viyash Scientific Limited VIYASH	₹6,642 Cr	67.6×	4.1×	11.0×	6.1%	5.2%	34.0%
Supriya Lifescience Limited SUPRIYA	₹6,473 Cr	35.7×	6.2×	21.8×	17.5%	25.3%	21.6%
Sun Pharma Advanced Research Company Limited SPARC	₹5,442 Cr	3.5×	4.1×	3.8×	116.0%	82.7%	98.9%
Bliss GVS Pharma Limited BLISSGVS	₹5,434 Cr	42.8×	4.6×	32.5×	10.8%	13.9%	7.2%
Suven Life Sciences Limited SUVEN	₹5,044 Cr	—	11.7×	—	-46.7%	-3886.6%	-19.3%
RPG Life Sciences Limited RPGLIFE	₹4,589 Cr	38.4×	12.1×	—	31.5%	0.2%	—

Peer comparison verdict

Themis is fairly valued relative to sector peers — trading near the sector median on key multiples (P/E ~38.4×, EV/EBITDA ~19.3×). Focus on execution quality and earnings trajectory from here.

Business quality

Valuation

P/E ratio

37.2×

P/B ratio

—

EV/EBITDA

—

Price/Sales

—

Returns

ROE

9.2%

ROCE

—

ROA

—

Growth

Revenue CAGR (3yr)

—

EPS CAGR (3yr)

—

Efficiency

Asset turnover

—

FCF yield

—

Dividend yield

—

Liquidity & Solvency

Debt / Equity

—

Debt / EBITDA

—

Interest coverage

—

Current ratio

—

Quick ratio

—

Financial health

Piotroski F-Score, Altman Z-Score, and key solvency ratios.

Financial health data is not yet available for this company.

Full financial data

Charts and annual statements for income, balance sheet and cash flow.

Income trend

Revenue, profit and margin trends over time.

Income statement data is unavailable for this company.

Cash flow

Where cash comes from and where it goes.

Cash flow data is not yet available for this company.

Balance sheet

Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.

Balance sheet data is not yet available for this company.

Numbers are illustrative — order-of-magnitude correct. For precise figures, refer to the company's annual report on BSE/NSE.

Shareholding pattern

Who owns this company and how that has changed.

Shareholding data is not yet available for this company.